Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:drug |
| gptkbp:administrationFrequency |
every 2 weeks
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:M04AX07
|
| gptkbp:brand |
gptkb:Krystexxa
|
| gptkbp:CASNumber |
76860-92-9
|
| gptkbp:contraindication |
gptkb:G6PD_deficiency
|
| gptkbp:developer |
Savient Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
10-12 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
pegloticase
|
| gptkbp:indication |
refractory chronic gout
treatment-resistant gout |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
PEGylated recombinant uricase
|
| gptkbp:mechanismOfAction |
uricase enzyme
converts uric acid to allantoin |
| gptkbp:molecularWeight |
~540 kDa
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
anaphylaxis
infusion reaction gout flare |
| gptkbp:usedFor |
treatment of chronic gout
|
| gptkbp:bfsParent |
gptkb:M09AX07
|
| gptkbp:bfsLayer |
7
|